NAVLIN Daily NewsCheckout Today’s News
China's State Council issued a national guidance document on drug pricing for the first time since liberalizing prices in 2015. It addresses the entire supply chain, from R&D to distribution, aiming for a market-driven system while balancing costs and innovationThe document encourages fair pricing for innovative drugs, incorporates commercial insurance to ease reliance on national funds, and plans to unify China's drug market by cutting local protectionism and promoting online price comparisonsFor the next decade, this document will guide drug pricing reform, eliminate fragmented governance, and diversify payment systems, blending national insurance, commercial insurance, and charitable funding to improve patient access
The Centers for Medicare & Medicaid Services (CMS) published its Calendar Year (CY) 2027 Medicare Advantage (MA) and Part D Rate Announcement this week, which codifies changes Medicare Part D introduced by the Inflation Reduction Act and previously implemented through guidanceThese changes include eliminating the coverage gap phase and restructuring of benefit phases that began in 2025, the annual out-of-pocket cap, deductible protections, and other updatesThe finalized polices are effective June 1, 2026, and are applicable to coverage beginning January 1, 2027
U.S. President Donald Trump's Fiscal Year (FY) 2027 budget proposal calls for an overall reduction in federal health agency spending, but supports several U.S. Food and Drug Administration (FDA) initiatives aimed at encouraging domestic development and manufacturing of drugs, as well as speeding development timeKey proposals include an alternative Investigational New Drug (IND) pathway to accelerate Phase 1 clinical development; a request of $9 million to fund FDA “PreCheck” to accelerate domestic manufacturing facility establishment, as well as a legislative proposal to let domestic generic manufacturers file Paragraph IV certifications one month before foreign competitors; and a request to create a new abbreviated licensure pathway for biological productsThe FDA also calls for additional statutory authority to regulate direct-to-consumer (DTC) prescription drug advertising
Hong Kong's Department of Health is rolling out its own system to evaluate and approve drugs locally. Instead of waiting on foreign regulators, the new process was initiated for approvals for new strengths, dosages, forms, and uses of existing registered chemicalsApplications are now open, with the DH reviewing clinical data, safety, and quality directlyTo guide applicants, the DH will host online seminars next month, explaining the step-by-step evaluation process
The Netherlands Minister of Health, Welfare, and Sport (VWS) has announced conditional admission (VT) of Orchard Therapeutics’ Libmeldy (atidarsagene autotemcel) in the basic package for the treatment of metachromatic leukodystrophy (MLD) in children with the early-juvenile form, with early clinical manifestations of the disease, who are able to walk independently and before the onset of cognitive declineThe VT process enables temporary reimbursement for patients with serious conditions and unmet needs, even when treatments do not yet fully meet the “state of science and practice” (SWP) criteria. Continued inclusion in the basic package depends on subsequent evidence generation and successful price negotiations, while failure to meet these requirements may lead to removal from reimbursementLibmeldy was already approved for inclusion in the basic package for asymptomatic MLD patients in 2024
Sweden launched an investigation to completely overhaul its pharmaceutical pricing system in the face of growing geopolitical pressure, including the growing threat of Most Favored Nation (MFN) drug pricing policyIn one of the first formal ex-U.S. governmental responses to MFN, the inquiry will consider solutions for establishing a single, “coherent” organization to address future healthcare needs and the introduction of new pharmaceutical products. The investigation will also consider options for introducing risk and cost-sharing models between the state and the regions, as well as options for a state-governed organization tasked with handling negotiations with manufacturers regarding confidential prices for their productsHowever, the inquiry is not expected to conclude until the end of 2027 and any reform would likely be implemented after 2028
Emcure Pharmaceuticals has announced a major price reduction for its weight management drug Poviztra (semaglutide), cutting the starting dose by up to 55% in a move aimed at significantly expanding patient access in IndiaUnder the revised pricing, effective April 3, 2026, Poviztra 0.25 mg will now cost ₹3,999 per month ($48 USD) or ₹999 per week ($12 USD), inclusive of taxes, down from ₹8,790 ($105 USD)Across all dosage strengths, prices have been reduced by an average of 47%
Last week, NAVLIN Daily brought you key market access developments from across the globe. The Trump administration advanced plans to formalize MFN drug pricing, South Korea approved major pricing reforms, and Germany’s FKG proposed GKV reforms In the UK, the government continued to come under pressure from big pharma companies to raise prices to mitigate the global spillover impact In India, Novo Nordisk dramatically cut the prices of Ozempic and Wegovy following last week’s semaglutide patent cliff, to compete with the wave of generic competition
While reeling from the current U.S. administration’s vaccine-critical policies and their effect on global access, vaccine industry leaders are mulling over ways to eventually build a future, more sustainable systemRobert Califf, Former U.S. Food and Drug Administration (FDA) Commissioner, summarized, “We have to put Humpty Dumpty back together again, but not exactly the way it was, because some people had significant issues with how it was before”“We have a Star Trek innovation system and a Flintstone delivery system,” said Atul Gawande, Professor of the Practice of Surgery, Brigham and Women’s Hospital, Harvard Medical School, who stressed that universal primary care would significantly improve health outcomes
At the World Vaccine Congress, industry leaders discussed the challenges that complicate building an international ecosystem to support biosecurityPartners must be arranged across the full product life cycle in advance of an outbreak for the chain to run smoothly, but some governments are less connected, and companies are not always driven or able to hold marketing dossiers for less profitable productsPanelists called for preemptive partnership development and continuous investment in innovation, even in peacetime
650+
+99%
<24
4,000+
24x7
99.5%
